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Abstract
Background: Effective treatment of paroxysmal atrial fibrillation (AF) is essential for reducing the risk of stroke and
heart failure. Cryoballoon (CB) ablation has been developed as an alternative to the use of radiofrequency (RF)
energy for electrical isolation of the pulmonary veins. Herein, we provide long-term data regarding the efficacy of
CB ablation in comparison to RF.
Methods: FreezeAF was a randomised non-inferiority study comparing CB ablation with RF ablation for the
treatment of patients with drug-refractory paroxysmal AF. Procedural success for the long-term follow-up
(30 months) was defined as freedom from AF with an absence of persistent complications.
Results: Of the 315 patients that were randomised and received catheter ablation, 292 (92.7%) completed the
30-month follow-up (147 in the RF group and 145 in the CB group). The baseline characteristics of the RF and CB
groups were similar. Single-procedure success was achieved by 40% of patients in the RF group and 42% of the
CB group (p < 0.001 for non-inferiority). When including re-do procedures in the analysis, the multiple procedure
success rate was 72% in the RF group and 76% in the CB group.
Conclusion: The data provide long-term evidence that CB ablation is non-inferior to RF ablation, with high
proportions of patients reporting freedom from AF 30 months after the index procedure.
Trial registration: ClinicalTrials.gov Identifier: NCT00774566; first registered October 16, 2008; first patient included
October 20, 2008.
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Background
Atrial fibrillation (AF) is associated with an increased
risk of stroke, heart failure, and death [1, 2]. While anti-
arrhythmic drugs (AADs) benefit some patients, they are
often inadequate and have been associated with intoler-
ance due to adverse events [3]. The development of
catheter ablation has provided patients with an alterna-
tive solution, one which has shown efficacy as both a
first- and second-line treatment for AF [4]. Indeed,
guidelines now state that drug-refractory paroxysmal AF
is a class I, level A indication for catheter ablation [5].
The most common approach to this is the electrical
isolation of the pulmonary veins (PV) by the creation of
circumferential lesions around the right and left PV
ostia. Such lesions have most commonly been formed
using point-by-point application of radiofrequency (RF)
energy. However, this procedure is complex and has
been associated with serious complications, including
cardiac tamponade [6]. A more recently developed alter-
native is the application of cryo-energy via a balloon
catheter. This technique enables the lesion to be pro-
duced in a single step, thereby potentially reducing the
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length of the procedure. However, it also requires more
extensive use of fluoroscopy and can cause phrenic
nerve injury as well as cardiac tamponade [7, 8].
Good outcomes after cryoballoon (CB) ablation have
been demonstrated, with high proportions of patients
remaining free from AF after long-term follow-up [7, 9, 10].
A number of studies have compared RF with CB ablation
for the treatment of paroxysmal AF, and have found similar
procedural success rates [6, 11–15]. However, there are few
studies that are both randomised and involve an appropri-
ate number of patients with a sufficiently long follow-up
period for providing a robust comparison of the efficacy of
the two ablation methods. One such study is FreezeAF,
which demonstrated non-inferiority of CB to RF at both 6
and 12 months post-procedure [16]. The primary endpoint
of freedom from AF, with no persistent complications,
was achieved by 73% and 75% of the CB and RF
groups (per-protocol [PP]), respectively, at 12 months
(p < 0.001 for non-inferiority). Non-inferiority was
also observed in the FIRE AND ICE trial, where 1-year
Kaplan–Meier estimates for clinical failure after
12 months were reported to be 34.6% and 35.9% for CB
and RF, respectively (p < 0.0001 for non-inferiority) [8, 17].
In the Cryo Versus RF trial, procedural success was
reported to be higher for CB ablation compared to RF, with
single-procedure success rates at 12 months being 76%
and 47%, respectively (p < 0.001) [18].
These data demonstrate the potential of CB ablation for
the treatment of paroxysmal AF; however, long-term
follow-up evidence is lacking. Here, we present data col-
lected at 30 months post-procedure in the FreezeAF trial.
Methods
FreezeAF is a prospective randomised controlled trial de-
signed to assess whether pulmonary vein isolation (PVI)
with the Arctic Front Cardiac CryoAblation Catheter Sys-
tem (Medtronic, Inc., Minneapolis, MN) is non-inferior to
that achieved using standard RF ablation [19]. Random
number generation software was utilised to assign patients
to one or other of the PVI techniques. The first patient
was included on October 20, 2008. Following the proced-
ure, there was a blanking period of 3 months. Follow-up
clinical visits were then conducted at 3, 6, and 12 months.
After completion of the follow-up within the scope of the
trial, continued clinical visits and Holter ECG recordings
were performed in our outpatient department on a yearly
basis. Patients who refused to come to a follow-up were
contacted by telephone and ECG documentation was
obtained by the primary care physician. For patients lost
to follow up, information whether the patient was still
alive was obtained from the primary care physician. For
this analysis a 30 month follow-up was performed.
All patients that were included in the study provided
written informed consent. The trial was approved by
the ethics committee at the University of Freiburg
(September 15th, 2008), and was conducted in accord-
ance with the Declaration of Helsinki and its amendments.
Patients
Patients that had experienced at least two episodes of
paroxysmal AF (of which at least one was documented)
within the 3 months prior to enrolment were included.
Further inclusion criteria included an age of between 18
and 75 years, and documented inefficacy of at least one
AAD. Patients were excluded if they presented with a
left atrium of >55 mm, displayed evidence of left atrial
thrombus, had previously undergone left atrial surgery
or ablation, had an ejection fraction of <40%, had heart
failure of New York Heart Association (NYHA) class III
or IV, had a mitral prosthesis, had suffered a myocardial
infarction (MI) within the previous 3 months, had
undergone percutaneous coronary intervention (PCI) or
cardiac surgery within the previous 3 months, had suf-
fered a stroke or transient ischaemic attack (TIA) within
the previous 6 months, were pregnant, or had a life ex-
pectancy of less than 1 year. A full list of inclusion and
exclusion criteria has previously been published [19].
Procedures
Transoesophageal echo was routinely performed in
patients undergoing left-atrial ablation and independent
of any potential previous anticoagulation. It was also
routinely performed in patients undergoing right-atrial
ablation but without a 4-week course of anticoagulation
(VKA, NOAC).
A detailed description of the ablation procedures that
were performed has been published previously [16, 19].
Briefly, RF ablation was carried out using an irrigated tip
catheter in conjunction with a 3D navigation system
(Ensite NavX/Velocity, St Jude Medical, St Paul, MN;
CARTO-3, Biosense Webster Inc., Diamond Bar, CA).
CB ablation was primarily performed using the Arctic
Front Cardiac CryoAblation Catheter System and the
FlexCath Steerable Sheath (Medtronic, Minneapolis,
MN). A small number of procedures were performed
using the second generation Arctic Front Advance. A
28 mm balloon was used preferentially, although a
change to a 23 mm balloon was permitted if deemed
necessary. The investigator identified the presence of a
common ostium of the left sided based on angiography.
All patients received anticoagulation (VKA or NOAC)
throughout the 4 weeks prior to the index procedure
and the subsequent 6 months. VKAs were bridged with
subcutaneous heparin was used if patients were receiv-
ing phenprocoumon and had an international normal-
ised ratio (INR) of <2; otherwise (INR >2), VKAs were
not interrupted. DOACs were not interrupted in any
case and also given in the morning prior to ablation.
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AADs were discontinued 4 to 5 half lives prior to the
ablation procedure, and beta blockers were the only
drugs administered following it.
Patients were followed in 6 months intervals on an
ambulatory basis. The visit included a 7-day Holter elec-
trocardiogram. In case the patient was not able to attend
the visit, the information were requested from the treat-
ing general practitioner/office based cardiologist. Further
ablation procedures could be carried out after 6 months
had elapsed if deemed necessary. In these cases, the
same energy source as that used for the index procedure
was employed.
Outcomes
Procedural success was defined as freedom from AF, in
combination with an absence of persistent complications
(after the 3-month blanking period). Persistent compli-
cations were defined as those classed as major or symp-
tomatic, and that remained present 6 months after the
procedure. Outcomes were assessed with regard to the
success of a single procedure, and as success after one
or more procedures. Procedural characteristics and
safety outcomes were analysed at 6 and 12 months, and
have been published elsewhere [16].
Statistics
The evaluation criteria single as well as multiple proced-
ure success were evaluated for the intention-to-treat
(ITT) population.
The test for non-inferiority was formulated in terms of
the rate of procedural success at the follow-up point for
the patients that had undergone the CB procedure (PCB)
and those that had undergone the RF procedure (PRF).
The null hypothesis (H0) was thereby defined as: PCB –
PRF ≤ −δ, where δ = 0.15 [19]. The non-inferiority test
for rates according to Farrington and Manning was per-
formed at a one-sided significance level of α = 2.5% [20].
Data are presented as means with standard deviations
(SD), medians with first and third quartiles, or absolute
values with percentages. Multiple logistic regression
analysis was used to assess the influence of both clinical as
well as procedure-specific factors on single-procedure suc-
cess. To this end logistic regression models were fitted for
the overall population, the RF group (including RF specific
covariates) and the CB group (including CB specific covar-
iates). Due to the multitude of factors of interest and the
resulting instability of standard logistic regression, we
used Firth’s penalized logistic regression to obtain stable
results [21]. Statistical analysis was performed using R
v3.13 and the ‘mice’ package (Multivariate Imputation by
Chained Equations) v2.22 [22]. All model variables were
included in the multiple imputation procedure (full pre-
dictor matrix) to minimise bias from the imputation
method and 10 datasets were imputed.
Results
Of the 315 patients that were randomised and received
catheter ablation, 292 (92.7%) completed the 30-month
follow-up (Fig. 1). The median age of the patients was
61.0 years, and 60.3% were male (Table 1). The baseline
characteristics of the RF group (N = 147) and the CB
group (N = 145) did not differ significantly, although a
common ostium was slightly more prevalent in the RF
group compared to CB (23.8% vs. 13.8%; p = 0.04). A
total of 73.3% of patients had been treated with phen-
procoumon, while 26.0% were taking a direct acting oral
Fig. 1 Patient flow, including planned sample size recalculation. *The initial sample size calculation resulted in 244 patients, which was readjusted
in March 2011 after a pre-specified blinded sample size recalculation [16, 33]. Patients withdrawing consent prior to treatment were unaware of
the assignment and were excluded from the population. Patients that refused a follow-up were contacted by phone to verify that they were alive,
though no heart rhythm was obtained. RF, radiofrequency; CB, cryoballoon
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anticoagulant (DOAC) and 11.9% were additionally
taking a platelet inhibitor. Again, there were no signifi-
cant differences between the RF and CB groups. Further
details on the baseline characteristics, medications, and
risk indices (CHA2DS2-VASc, HAS-BLED) can be found
in our previous report, along with data concerning peri-
procedural complications [16]. Briefly, the occurrence of
vascular events (p = 0.372) and pericardial effusion
(p = 0.683) did not vary between the RF and CB groups,
while phrenic nerve palsy was observed exclusively in
the CB group (3 major events, 6 minor events).
Procedural success, defined as freedom from AF with an
absence of persistent complications, at 30 months after
the index procedure was achieved by 40% of patients in
the RF group and 42% of the CB group (p < 0.001 for
non-inferiority; Fig. 2). When taking multiple procedures
into account, procedural success was 72% and 76% for the
RF and CB groups, respectively (p = 0.006 for non-
inferiority; Fig. 3). The proportions of patients that had
undergone re-do procedures in order to achieve proced-
ural success increased from the 12-month to the 30-
month follow-up point, reaching 37% and 35% for the RF
Table 1 Patient characteristics
Total
(N = 292)
RF
(N = 147)
CB
(N = 145)
p-value
RF vs. CB
Male gender 176 (60.3) 83 (56.5) 93 (64.1) 0.22
Age (years)† 61.0 (54.8, 67.0) 60.0 (55.0, 67.5) 62.0 (54.0, 66.0) 0.96‡
Comorbidities
CAD 37 (12.7) 18 (12.2) 19 (13.1) 0.83†
Hypertension 187 (64.0) 95 (64.6) 92 (63.4) 0.93
Diabetes 28 (9.6) 16 (10.9) 12 (8.3) 0.58
Vascular disease 15 (5.1) 11 (7.5) 4 (2.8) 0.12
Common ostium 55 (18.8) 35 (23.8) 20 (13.8) 0.04
Prior medication
Phenprocoumon 214 (73.3) 108 (73.5) 106 (73.1) 1.00
DOAC 76 (26.0) 37 (25.2) 39 (26.9) 0.84
Platelet inhibitora 34 (11.9) 21 (14.7) 13 (9.2) 0.20
Bridgingb 40 (14.1) 24 (16.9) 16 (11.3) 0.23
†Data given as median (p25, p75)
‡P-value calculated using Mann-Whitney U-test. All other p-values calculated using chi-square test
aN: total, 286; RF, 143; CB, 142
bN: total, 284; RF, 142; CB, 142. CAD, coronary artery disease; DOAC, direct oral anticoagulant
Fig. 2 Freedom from AF, without persistent complications (ITT analysis, single procedure success). RF: N = 147; CB: N = 145. P-values are
for non-inferiority
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and CB groups, respectively. It should be noted that
between 12 and 30 months, six patients in the CB group
underwent a re-do procedure using RF (based on a
random decision at the time of recurrence), while none of
the RF group underwent a CB procedure. After the first
six patients crossed over a decision was made to treat
subsequent patients according to their group assignment
for recurrences.
The only variable that was found to be predictive of single
procedure success was being male (Table 2). However, this
Fig. 3 Freedom from AF, without persistent complications (ITT analysis, multiple procedure success). Thirty-month analysis includes 6 CB patients
who underwent RF as a re-do procedure. No RF patients had a CB re-do procedure. P-values are for non-inferiority
Table 2 Adjusted odds ratiosa for achievement of single procedure success
Total (N = 292) RF (N = 147) CB (N = 145)
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Group: CB 1.02(0.45–2.32) 0.96 N/A N/A N/A N/A
Age 1.02 (0.96–1.08) 0.50 1.05 (0.95–1.17) 0.31 1.00 (0.95–1.07) 0.90
Gender: male 3.42 (1.09–10.71) 0.04 9.77 (1.36–70.08) 0.02 2.12 (0.70–6.42) 0.19
CAD 1.32 (0.25–6.96) 0.74 1.93 (0.12–30.67) 0.64 1.18 (0.17–8.06) 0.87
Hypertension 0.53 (0.19–1.51) 0.24 0.11 (0.01–1.33) 0.08 0.85 (0.30–2.40) 0.76
Diabetes 0.72 (0.22–2.43) 0.60 0.63 (0.08–4.86) 0.66 0.94 (0.20–4.50) 0.94
Vascular disease 0.57 (0.07–4.37) 0.59 0.47 (0.02–14.38) 0.66 0.30 (0.01–6.06) 0.43
Common ostium 1.36 (0.42–4.40) 0.60 2.26 (0.31–16.57) 0.42 1.11 (0.25–4.98) 0.89
Bridging 0.92 (0.32–2.65) 0.88 0.74 (0.15–3.72) 0.72 1.57 (0.31–8.08) 0.59
Platelet inhibitor 0.81 (0.20–3.31) 0.77 0.52 (0.08–3.57) 0.51 1.08 (0.14–8.01) 0.94
DOAC vs. Phenprocoumon 3.91 (0.30–50.12) 0.29 3.14 (0.24–40.93) 0.28 1.21 (0.31–4.66) 0.78
Follow-up time 0.92 (0.75–1.13) 0.44 1.01 (0.82–1.24) 0.94 0.90 (0.67–1.20) 0.47
NavX navigation system N/A N/A 0.37 (0.06–2.12) 0.27 N/A N/A
Balloon size: 23 mm N/A N/A N/A N/A 1.89 (0.44–8.07) 0.39
Balloon size: both N/A N/A N/A N/A 0.65 (0.03–12.44) 0.78
Second generation balloon N/A N/A N/A N/A 9.77 (0.30–320.56) 0.20
Achieve catheter N/A N/A N/A N/A 1.24 (0.38–4.10) 0.72
Multiple balloons N/A N/A N/A N/A 1.26 (0.10–16.20) 0.86
aAdjusted for all applicable variables. N/A: not applicable; CAD, coronary artery disease. Procedural success defined as freedom from AF with an absence of
persistent complications, at 30 months
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was only true for the overall population (OR: 3.42; 95% CI:
1.09–10.71; p = 0.04) and the RF group (OR: 9.88; 95% CI:
1.36–70.08; p = 0.02). The type of procedure was not pre-
dictive of success (OR: 1.02; 95% CI: 0.45–2.32; p = 0.96)
which is in line with the significant result of the non-
inferiority test. The use of the second generation balloon
((Arctic Front Advance Cardiac CryoAblation Catheter
System (Medtronic Inc., Minneapolis, MN)) appeared to be
predictive of improved efficacy; however, due to the later
availability and the resulting small number of proce-
dures (n = 22) the confidence interval was extremely
large (OR: 9.77; 95% CI: 0.30–320.56; p = 0.20) (for
details see Table 3). Of the 22 procedures conducted
with the new balloon, 17 were successes while only 42
of the 120 procedures with the old balloon were suc-
cessful after the first procedure. With the use of the
second generation balloon the mean procedure time
was reduced from 170.5 min to 103.2 min, which corre-
sponds to a mean difference of 67.3 min (95% CI: 49.7–
84.9 min; p < 0.0001). There also was a reduction of the
fluoroscopy duration (27.2 vs. 18.6 min; mean differ-
ence 8.6 min; 95% CI: 3.8–13.2 min; p = 0.0004).
Discussion
The randomised FreezeAF trial was performed in order
to evaluate the efficacy of CB ablation as an alternative
to the established RF approach. After an extended
follow-up of 30 months, CB ablation was non-inferior to
RF in terms of freedom from AF, without persistent
complications.
PV isolation using a CB has a number of potential
advantages to that using RF ablation. Firstly, the overall
procedure time is generally lower, owing to the one-step
lesion-formation process. Indeed, in the FreezeAF trial,
the median procedure time was 174 min for the RF
group and 161 min for the CB (p = 0.006) [16]. This is
in agreement with the FIRE AND ICE study, where pro-
cedure duration was 140.9 min for RF and 124.4 min for
CB (p < 0.001) [8]. Although the duration of fluoroscopy
was comparable between the two procedure types in Free-
zeAF, CB required a higher X-ray dose [16]. However, in
the present analysis, a comparison of the first and second
generation CBs showed not only a significant reduction in
fluoroscopy time with the newer model, but also a slightly
lower X-ray dose. While only a small number of proce-
dures were performed using the second generation CB,
other recent studies have also demonstrated significant
advantages over the earlier version in terms of both
procedure time and fluoroscopy time [23, 24]. Further
studies involving the later generations of RF and CB
devices are needed in order to determine if there remains
significant differences in procedural duration and
fluoroscopy between them.
There is a growing body of evidence from registries
[6, 25] and clinical studies [11–15] demonstrating that
CB ablation is similar in efficacy to RF; however, there
are only limited data from randomised controlled trials.
We previously demonstrated that procedural success with
the CB method was non-inferior to that with the RF, at
both 6 and 12 months post-ablation [16]. Furthermore,
periprocedural complication rates were not significantly
different between the two methods, with the exception of
a higher incidence of phrenic nerve palsy in the CB
patients [16]. Here, we have re-evaluated the original
primary endpoint to include the patients with efficacy
information available after 30 months. The finding of non-
inferiority was maintained after this extended period of
time. These data are in agreement with those obtained in
the randomised FIRE AND ICE study, where Kaplan–
Meier estimates of procedural failure were calculated to
be 35.9% and 34.6% at 1 year, respectively (p < 0.001 for
non-inferiority) [8, 17]. While the maximum follow-up
time was 33 months in this case, patient numbers declined
greatly after the first year, with the mean follow-up being
1.5 years. In FreezeAF, 92.7% of the patients that under-
went the index procedure completed the 30-months
follow-up period, providing a robust estimate of long-
term procedural success.
Multivariable analysis demonstrated that being male
was predictive of single procedure success at 30 months
for patients undergoing the RF procedure, although the
confidence interval was large. In the Cryo Versus RF
trial, female gender was identified as being predictive of
recurrent atrial arrhythmia after adjustment for the abla-
tion method used (HR: 2.22; 95% CI: 1.22–4.01;
p = 0.009) [18]. As in our study, Neumann et al. found
no association between gender and procedural success
when using the CB technique [26]. Out of all the vari-
ables assessed in our analysis, none were found to have
substantial predictive value for single procedure success.
This included procedural characteristics such as the use
of the NavX 3D navigation system as opposed to the
CARTO (RF procedure), and use of the Achieve map-
ping catheter as opposed to the Lasso (CB procedure).
For the CB procedure, use of the second generation
Table 3 Subgroup analyses CB-1 versus 2
CB – 1
(N = 120)
CB – 2
(N = 22)
p-value
Isthmus ablation (RF) 15 (13%) 4 (18%) 0.61
Common ostium 15 (13%) 5 (23%) 0.35
Total procedure time (min) 170.5 103.2 <0.001
X-ray duration (min) 27.2 18.6 0.0004
X-ray dose (cGy*cm2) 77.4 55.0 0.10
Single procedure success 42 (35%) 17 (67%) 0.001
CB-1: first generation Arctic Front; CB-2: second generation Arctic Front
Advance (both Medtronic, Minneapolis, MN)
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cryoballoon appeared to increase the likelihood of pro-
cedural success; however, the confidence interval was
extremely large. It is possible that with a higher number
of patients, this difference could be confirmed to be sta-
tistically significant. As the present study was initiated in
2008, the majority of subjects underwent ablation using
the first generation balloon, preventing us from accur-
ately comparing the different models. Some recent stud-
ies have found that procedure time appears to be shorter
with the Advance model, while long-term freedom from
AF is superior [23, 24]. One study found that the rate of
phrenic nerve palsy was higher with the second gener-
ation CB, [27] while other studies have reported no
difference [23, 24]. Improvements in RF systems have
also been introduced in recent years, the main develop-
ment being contact force sensing [28, 29]. A limitation
to the present study is that at the time of its initiation,
contact force systems were not yet available. The ana-
lysis is therefore primarily a comparison of the first
generation RF and CB devices, albeit with a small num-
ber of second generation CB procedures included. The
FIRE AND ICE study had a similar limitation, with first
and second generations of both types of device used [8].
In fact, the majority of patients in the RF group received
treatment with the first generation device, while for the
CB procedure, there were significantly more second gen-
eration devices used. Notably, there are early indications
that the non-inferiority of CB compared to RF could be
maintained for the later generations of catheter ablation
systems [13, 15, 30]. However, at present, there are no
long-term data available concerning the efficacy of the
newer systems. Comparisons of the early models there-
fore provide a valuable indication of the long-term
success of the two ablation techniques.
One potential source of bias in the comparison of the
long-term outcomes of RF and CB ablation is the higher
prevalence of a common ostium that was observed in
the RF group. As the CB approach is potentially more
difficult in the presence of this defect, procedural suc-
cess rates may have been affected by this. However, the
presence of a common ostium was not found to be asso-
ciated with procedural success in the multivariate ana-
lysis, in either group, which is in agreement with other
studies [31, 32].
Conclusions
The therapeutic non-inferiority of CB ablation for the
treatment of paroxysmal AF has again been demon-
strated. In comparison with the traditionally-used RF
energy source, the cryo technique was found to be non-
inferior, which is in agreement with other studies.
Furthermore, the second generation balloon appeared to
be associated with more procedures being successful
after the first attempt than the previous model. We have
shown here that this non-inferiority continues long-
term, with the achievement of freedom from AF being
high 30 months after the index procedure. This ex-
tended follow-up of the FreezeAF trial provides evidence
that the CB should be considered as a viable alternative
to RF ablation for patients with paroxysmal AF.
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